Back to top

Analyst Blog

PerkinElmer(PKI - Analyst Report) reported third-quarter fiscal 2011 adjusted (excluding one-time expenses) earnings per share of 41 cents, beating the Zacks Consensus Estimate of 39 cents and exceeding the year-ago earnings per share of 31 cents. The results exceeded the company’s earlier guidance in the range of 37 cents to 39 cents.

Net income from continuing operations (as reported) rose just 0.6% year over year to $26.7 million (or 24 cents a share) in the reported quarter from $26.5 million (or 22 cents a share) in the prior-year quarter. Net income, on the other hand, rose sharply to $35.3 million (or 31 cents) from $13.4 million (or 11 cents) a year ago.


Revenues from continuing operations were $453.7 million in the reported quarter, up 8% year over year (up 4% on an organic basis), missing the Zacks Consensus Estimate of $470 million.

Segment-wise Revenue

Sales from the Human Health segment were $207.4 million, up 7% (up 2% on an organic basis) year over year. Revenues from the Environmental Health segment were $628.7 million, up 10% (up 6% on an organic basis).  


Company-wide adjusted operating margin at 14.2% was higher than 13.7% in the year-ago quarter. Adjusted operating margin for the Human Health segment was 19.5%, up 20 basis points (bps) year over year. Adjusted operating margin for the Environmental Health segment was 12.2%, lower 100 bps year over year.


The company has updated its adjusted earnings per share forecast for fiscal 2011 to a slightly higher range of $1.66 to $1.68 (earlier $1.64 to $1.68). Reported earnings from continuing operations are forecast in the range of 94 cents to 96 cents. Organic revenue is still expected to increase in the mid single digits. The Zacks Consensus Estimates for earnings and revenues, for 2011, are $1.66 and $1,926 million respectively.

PerkinElmer has established itself as a market leader, particularly in the genetic screening segment, and holds one of top two market share positions in several important subsets of the life sciences technology and genetic screening businesses.

It, however, operates in a highly competitive industry characterized by rapid technological change and evolving industry standards. As a result, the company must make large investments in R&D in order to maintain a competitive pipeline. PerkinElmer competes with Thermo Fisher Scientific (TMO - Analyst Report) among others.

The company continues to execute well across all its product lines aided by rebounding markets and cost containment efforts. Its transfer of select manufacturing to China has expanded operating margins. PerkinElmer has increased its productivity and improved product mix in favor of higher value added products. This has led to higher operating margins.

PerkinElmer's exposure to poor end market visibility might result in a relatively unattractive risk-reward trade-off for the stock. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%